CRC Research Update

  • SCREENING

    Non-Invasive Colorectal Cancer Screening Using Stool- and Blood-Based Tests

    A new review synthesizes evidence on fecal immunochemical testing (FIT), multi-omics stool DNA-FIT, multi-omics stool RNA-FIT, and blood-based assays for asymptomatic individuals at average risk, emphasizing the distinction between cancer detection and advanced precancerous lesion detection. (J Vis Exp)

  • SCREENING

    Real-Time AI-Assisted Detection of Colonic Lesions Using the iIDEAS Intelligent-C Module

    A prospective single-center validation study (NCT05784935) tested the iIDEAS-C computer-aided detection system during colonoscopy, with co-primary endpoints of adenomas per colonoscopy and lesion-level miss rate. (JGH Open)

  • RESEARCH

    PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

    Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep)

  • RESEARCH

    ctDNA in the Management of Resectable & Advanced Colorectal Cancer

    A structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing in stage I-III CRC and selected patients with resected or ablated oligometastatic stage IV disease. (Onco Targets Ther)

  • SCREENING

    Impact of the Australian National Bowel Cancer Screening Program on Stage at Diagnosis and Survival

    A retrospective cohort study of 881 colorectal cancer episodes from 2010 to 2024 examined overall survival differences between screen-detected and non-screen-detected cancers for each stage I-III; the Australian National Bowel Cancer Screening Program began in 2006, offering free faecal occult blood testing every 2 years to Australians aged 50-75 years. (ANZ J Surg)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

  • What Causes Colorectal Cancer in the Young?

    An age-specific attributable fraction analysis estimated population attributable fractions for lifestyle and medical risk factors across three age groups (30-49, 50-69, and ≥70 years), using birth-cohort-specific prevalence data from NHANES 1999-2002 and CRC incidence from Global Cancer Observatory 2022. (Eur J Cancer Prev)

This week's research spans screening technology, biomarker development, and resistance mechanisms in targeted therapy.